Medical Condition News

RSS

Respiragene test for lung cancer motivates smokers to quit smoking

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

1 Oct 2009

Less than half of men and women in Ontario with depression visit doctor for treatment

Less than half of men and women in Ontario who may be suffering from depression see a doctor to treat their potentially debilitating condition, according to a new women's health study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES).

1 Oct 2009

Immunocellular Therapeutics' pilot study can help in early cancer detection

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Data from this study demonstrated that ICT-109 had a statistically significant ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets.

30 Sep 2009

New treatment for chronic sinusitis from Summit Ear, Nose & Throat

Summit Ear, Nose & Throat is the first in the area to offer an exciting new treatment for chronic sinusitis (CRS) in an outpatient setting called FinESS™ Sinus Treatment. FinESS is a new balloon sinuplasty technique that is less invasive than traditional sinus surgery and that breaks the cycle of chronic sinusitis with immediate relief and lasting results.

30 Sep 2009

Omega-3 fatty acids prevent and slow age-related macular degeneration

Researchers are seeing more benefits of omega-3 fatty acids (omega-3s), such as their ability to help prevent and slow age-related macular degeneration (AMD), an eye disease that is the leading cause of severe vision loss in older people.

30 Sep 2009

Lumenis to discuss different treatment options for laryngeal cancer at 2009 AAO-HNS

Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.

From Lumenis Inc. 30 Sep 2009

SBIR grant from NIH to GenVec for metastatic cancer research

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.

30 Sep 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint.

30 Sep 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

Topcor launches Clipa for a Cure to support breast cancer research

October is National Breast Cancer Awareness Month and Topcor is introducing a new product to support breast cancer research.

30 Sep 2009

Oilfield leader builds unique colored rig to support breast cancer research

If you're seeing pink where you wouldn't normally expect in the Western states, you're not color blind. A Colorado-based company has built the Pink Rig, a hydraulic workover unit with snubbing capabilities that is literally painted pink.

30 Sep 2009

Hearing loss is a concern for all ages: Sonic Innovations

In conjunction with Hearing Aid Awareness Week, Sonic Innovations (www.sonici.com), a Utah-based global hearing aid manufacturer, warns that not being able to hear is more important to your health than you may think. Hearing loss has been linked to depression, anxiety and self-esteem issues.

30 Sep 2009

Study shows that exposure to radon gas leads to lung cancer

Exposure to radon gas in homes is the second leading cause of lung cancer after smoking, according to a study carried out by researchers from the University of Cantabria and the Babes-Bolyai University in Romania. The team has studied data on exposure to this element in a uranium mining area in Transylvania and in an area of granite in Torrelodones, Madrid

30 Sep 2009

Tβ4 therapy in EAE mice improves neurological functional recovery

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery.

30 Sep 2009

Sanofi-aventis announces study results comparing efficacy of Lantus to detemir

Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

30 Sep 2009

Researchers identify embryonic origin of Merkel cells

Publication in Journal of Cell Biology : researchers from ULB (IRIBHM) identify the embryonic origin of Merkel cells. Their research continue on an extremely aggressive cancer, the Merkel cell carcinoma

30 Sep 2009

Manic-depression not a lifelong disorder

Bipolar disorder, or manic-depression, causes severe and unusual shifts in mood and energy, affecting a person's ability to perform everyday tasks. With symptoms often starting in early adulthood, bipolar disorder has been thought of traditionally as a lifelong disorder. Now, University of Missouri researchers have found evidence that nearly half of those diagnosed between the ages of 18 and 25 may outgrow the disorder by the time they reach 30.

30 Sep 2009

SATAI invests $1.045 million in Azaya Therapeutics

SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009